Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report.

Raoul Kanav Khanna,Rabih Hage, Alexandre Hage,Vanessa Polin,Thomas Sené, Catherine Vignal-Clermont

MEDICINE(2018)

引用 1|浏览5
暂无评分
摘要
Rationale: The association between intracranial hypertension (ICH) and ulcerative colitis (UC) is rare. We report the unusual case of a male patient with UC and ICH in whom both conditions resolved with mesalazine therapy. Patient concerns: A 48-year-old Caucasian man presented to our department in June 2016 for decreased vision, transient visual obscuration, pulsatile tinnitus and headaches of 7 months duration. Bilateral optic disc swelling was found at fundus examination. Brain MRI excluded any brain tumor and lumbar puncture showed cerebrospinal fluid (CSF) opening pressure of 26cm of water with normal CSF contents. Diagnoses: Idiopathic ICH was suspected. Interventions: The patient was managed with oral acetazolamide. Headaches initially improved but the dosage could not be decreased under 750mg a day without recurrence of the symptoms. Extensive review of systems showed that the patient had active UC. He was given oral mesalazine, 2000mg a day. Outcomes: The symptoms of UC and ICH quickly resolved. Acetazolamide was progressively tapered over the course of the 9 subsequent months and the patient did not show any worsening of his symptoms or papilledema. Lessons: UC should be added to the list of disorders associated with ICH. In case of atypical ICH with drug dependency, investigations should seek for UC. Treating efficiently UC with mesalazine may improve ICH, suggesting an underlying inflammatory process.
更多
查看译文
关键词
inflammatory bowel disease,intracranial hypertension,mesalazine,ulcerative colitis
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要